Results 81 to 90 of about 3,654 (190)

STABILITY-INDICATING RP-HPLC METHOD FOR SIMULTANEOUS ESTIMATION OF SOFOSBUVIR, VELPATASVIR, AND VOXILAPREVIR IN BULK AND TABLET DOSAGE FORMS

, 2020
Objective: The present study was aimed to develop a novel, simple, rapid accurate and precise, stability-indicating reversed-phase high-performance liquid chromatography method for the simultaneous estimation of sofosbuvir, velpatasvir, and voxilaprevir ...
PADMINI M, VENKATA, D, GOWRI SANKAR
core  

Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients

, 2018
BACKGROUND & AIMS Sofosbuvir, an NS5B inhibitor, combined with velpatasvir, an NS5A inhibitor (SOF/VEL), produces high sustained virologic response rates 12 weeks after treatment (SVR12) in patients with genotype 1-6 HCV infection, and has no ...
Agarwal, Kosh, McNabb, Brian, Luisa M. Stamm, Mariño, Zoe, Castells, Lluís, William M.C. Rosenberg, John McNally, Arterburn, Sarah, Xavier Forns, Lluís Castells, Mani Subramanian, G., Müllhaupt, Beat, Gregory Camus, Jean-François Dufour, Stamm, Luisa M, McNally, John, Beat Müllhaupt, Camus, Gregory, Dufour, Jean-François, Mani Subramanian, G, Brainard, Diana M, Kosh Agarwal, Rosenberg, William M C, Brian McNabb, Zoe Mariño, Diana M. Brainard, Rosenberg, William M.C., Brainard, Diana M., G. Mani Subramanian, Forns, Xavier, Sarah Arterburn, Stamm, Luisa M.   +31 more
core   +1 more source

Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C

, 2018
To appraise the clinical and cost effectiveness of sofosbuvir velpatasvir voxilaprevir within its marketing authorisation for treating chronic hepatitis ...
Onyimadu, Oluchukwu, Harris, Petra, Kalita, Neelam, Cooper, Keith, Picot, Joanna   +4 more
core  

ANALYTICAL METHOD DEVELOPMENT AND VALIDATION FOR THE SIMULTANEOUS ESTIMATION OF SOFOSBUVIR AND VELPATASVIR DRUG PRODUCT BY RP-HPLC METHOD

, 2017
A novel reversed phase high performance liquid chromatography (RP-HPLC) method has been developed for the estimation of Sofosbuvir and Velpatasvir drug product by liquid chromatography.
Uppalapati.Jyothi*1, Dr.Parimi.Umadevi2
core   +1 more source

EXPERIENCE IN THE TREATMENT OF HEPATITIS C IN PREGNANT PATIENTS AT THE HEPATITIS CLINIC OF THE VERACRUZ HIGH SPECIALTY HOSPITAL

Annals of Hepatology
Introduction and Objectives: Currently, HCV treatment options during pregnancy are not well-defined. Typical clinical practice is to refer and link pregnant women for treatment after pregnancy and breastfeeding; however, in practice, very few have ...
Maria Teresa Guzmán Terrones, Eve Flynn Ferreira, Luis Del Carpio Orantes, Raúl Terrones Castro   +3 more
doaj   +1 more source

Real-world effectiveness of sofosbuvir/velpatasvir for the treatment of hepatitis C virus in prison settings

, 2022
20.500.12530/87870Plain language summary Achievement of elimination of HCV as a major public health threat requires focus on vulnerable populations such as people in prison.
de Ledinghen, Victor, Wong, Alexander, Vanstraelen, Kim, Mertens, Michael, Perez-Hernandez, Paco, Di Marco, Vito, Rosati, Silvia, Maida, Ivana, Campanale, Francesca, Jimenez, Elena, Hernandez, Candido, Bascia, Annalisa, Macedo, Guilherme, Ramroth, Heribert, Mangia, Alessandra, Fernandez-Rodriguez, Conrado, Ranieri, Roberto, Teti, Elisabetta, Ntalla, Ioanna, Brixko, Christian   +19 more
core   +1 more source

Sofosbuvir/Velpatasvir for the treatment of Hepatitis C Virus infection [PDF]

, 2018
Hepatitis C Virus (HCV) infection is major health problem worldwide, with 150 million infected people according to recent epidemiologic estimations.
Monti M, Gragnani L, Zignego AL
core   +1 more source

Deferred treatment with a fixed‐dose combination of sofosbuvir‐velpatasvir for chronic hepatitis C virus genotype 1, 2, 4 and 6 infection [PDF]

, 2019
Sofosbuvir‐velpatasvir is approved for the treatment of chronic hepatitis C virus (HCV) infection. In this single‐arm, open‐label, phase 3, deferred treatment study, we investigated the efficacy and safety of sofosbuvir‐velpatasvir among patients ...
Bernard Willems, Huang, KC, Tram T. Tran, Evguenia Svarovskaia, Davis, MN, Tarik Asselah, Obaid S. Shaikh, Shaikh, OS, John McNally, Nguyen, MH, Mindie H. Nguyen, Osinusi, A, Shafran, SD, Bourgeois, S, McNally, J, Philippe Mathurin, Svarovskaia, E, Brainard, DM, Willems, B, K. C. Huang, Asselah, T, Mathurin, P, Lai, CL, Tran, TT, Mitchell N. Davis, Stefan Bourgeois, Stephen D. Shafran, Ching‐Lung Lai, Diana M. Brainard, Anu Osinusi   +29 more
core   +1 more source

Comparative efficacy and safety of Sofosbuvir/Velpatasvir and Danoprevir for the treatment of chronic hepatitis C: the real-world data in China

BMC Gastroenterology
Background Sofosbuvir/Velpatasvir (Epclusa, ECS) is the first pan-genotype direct-acting antiviral agent (DAA) for hepatitis C virus (HCV) infection, and Danoprevir (DNV) is the first DAA developed by a Chinese local enterprise, which is suitable for ...
Yunjing Zhou, Minfeng Liang, Yiting Li, Xing Chen, Jie Yang, Honglian Bai, Yingzi Long, Xiaohong Zhang, Chaoshuang Lin   +8 more
doaj   +1 more source

Eight-week treatment with sofosbuvir/velpatasvir may be effective in curing hepatitis C in children

Pediatria Polska
Sofosbuvir/velpatasvir (SOF/VEL) is a safe and effective regimen used for the treatment of chronic hepatitis C. The standard treatment duration is 12 weeks. There are no data available to support the shortened treatment.
Maria Pokorska-Śpiewak, Anna Dobrzeniecka, Magdalena Marczyńska   +2 more
doaj   +1 more source